<DOC>
	<DOCNO>NCT02110524</DOCNO>
	<brief_summary>The purpose study assess safety inhibition restenosis CVI Paclitaxel-coated PTA Balloon Catheter treatment de-novo occluded/stenotic reoccluded/restenotic superficial femoral ( SFA ) popliteal artery . The primary endpoint analysis late lumen loss six ( 6 ) month .</brief_summary>
	<brief_title>CVI Drug Coated Balloon First In Human Trial</brief_title>
	<detailed_description>Prospective , control , multi-center , open , single arm study Main cohort : 50 ; pre-specified treatment group : 30 . Total patient : 80</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Subjects symptomatic leg ischemia , require treatment SFA popliteal ( P1 segment ) artery De novo restenotic lesion ( ) &gt; 70 % within SFA popliteal artery single limb ≥3 cm ≤15 cm cumulative total length ( visual estimation ) . Target vessel reference diameter ≥3 mm ≤7 mm ( visual estimation ) . Rutherford classification 2 , 3 4 Lesion length &lt; 3 cm &gt; 15 cm normal proximal arterial segment duplex ultrasound velocity ratio measure . Outflow artery ( distal popliteal , anterior posterior tibial peroneal artery ) significant lesion ( ≥ 50 % stenosis ) may treat procedure . Treatment contralateral limb procedure within 30 day study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Peripheral Arterial Disease</keyword>
</DOC>